GLP-1 receptor agonist medications are FDA-approved for adults who meet one of the following criteria: a body mass index (BMI) of 30 or higher (classified as obesity), or a BMI of 27 or higher (overweight) combined with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease
its expression in testis can be suppressed by estrogens (Doege et al., Mechanisms of entry into enterocytes Both ascorbate and DHA can enter enterocytes via SVCT and GLUT transporters, respectively
Ease of entry matters as much as breadth of content
Metabolic signatures of exercise in human plasma
A systematic review of multiple studies shows that weight regain is a common outcome
This injection promotes nerve health and function, reducing the risk of neuropathy and enhancing cognitive performance through its rich formulation of B vitamins